161 related articles for article (PubMed ID: 32554608)
1. Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma.
Ladányi A; Papp E; Mohos A; Balatoni T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Ferrone S
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554608
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy.
Balatoni T; Mohos A; Papp E; Sebestyén T; Liszkay G; Oláh J; Varga A; Lengyel Z; Emri G; Gaudi I; Ladányi A
Cancer Immunol Immunother; 2018 Jan; 67(1):141-151. PubMed ID: 28988380
[TBL] [Abstract][Full Text] [Related]
3. The proportion of circulating CD45RO
Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
[TBL] [Abstract][Full Text] [Related]
4. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C
Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045
[TBL] [Abstract][Full Text] [Related]
5. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
7. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
9. HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab.
Ladányi A; Hegyi B; Balatoni T; Liszkay G; Rohregger R; Waldnig C; Dudás J; Ferrone S
Pathol Oncol Res; 2022; 28():1610297. PubMed ID: 35531074
[TBL] [Abstract][Full Text] [Related]
10. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Koguchi Y; Iwamoto N; Shimada T; Chang SC; Cha J; Curti BD; Urba WJ; Piening BD; Redmond WL
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34620702
[TBL] [Abstract][Full Text] [Related]
11. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
[TBL] [Abstract][Full Text] [Related]
12. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
13. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
14. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Kakavand H; Jackett LA; Menzies AM; Gide TN; Carlino MS; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Mod Pathol; 2017 Dec; 30(12):1666-1676. PubMed ID: 28776578
[TBL] [Abstract][Full Text] [Related]
15. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM
JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543
[TBL] [Abstract][Full Text] [Related]
16. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Stein JE; Soni A; Danilova L; Cottrell TR; Gajewski TF; Hodi FS; Bhatia S; Urba WJ; Sharfman WH; Wind-Rotolo M; Edwards R; Lipson EJ; Taube JM
Ann Oncol; 2019 Apr; 30(4):589-596. PubMed ID: 30689736
[TBL] [Abstract][Full Text] [Related]
17. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Yuan J; Postow MA; Wong P; Capone M; Madonna G; Khammari A; Schilling B; Sucker A; Schadendorf D; Martus P; Dreno B; Ascierto PA; Wolchok JD; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Oct; 22(19):4848-4858. PubMed ID: 27169993
[TBL] [Abstract][Full Text] [Related]
18. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Diem S; Hasan Ali O; Ackermann CJ; Bomze D; Koelzer VH; Jochum W; Speiser DE; Mertz KD; Flatz L
Cancer Immunol Immunother; 2018 Jan; 67(1):39-45. PubMed ID: 28894934
[TBL] [Abstract][Full Text] [Related]
19. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
20. Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Postow MA; Chasalow SD; Kuk D; Panageas KS; Cheng ML; Yuan J; Wolchok JD
Melanoma Res; 2020 Feb; 30(1):71-75. PubMed ID: 31425479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]